<DOC>
	<DOCNO>NCT00514579</DOCNO>
	<brief_summary>The hypothesis study double unit umbilical cord blood transplantation adult associate one year survival rate least 40 % .</brief_summary>
	<brief_title>Adult Double Cord Blood Transplant Study</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age 22 50 year Patients one follow hematological malignancy : Acute myelogenous leukemia ( AML ) : Complete first remission ( CR1 ) high risk relapse Complete second remission ( CR2 ) Acute lymphoblastic leukemia ( ALL ) : Complete first remission ( CR1 ) high risk relapse Complete second remission ( CR2 ) Acute undifferentiated leukemia ( AUL ) biphenotypic leukemia : CR1 CR2 Myelodysplastic Syndrome ( MDS ) one follow : Low Intermediate1 International Prognostic Scoring System ( IPSS ) score Lifethreatening neutropenia thrombocytopenia ; Platelet transfusion dependence Intermediate2 High IPSS score Therapyrelated disease : patient history chemotherapy current evidence MDS Patients adequate organ function performance status criterion Two Suitable Umbilical Cord Blood Units : cryopreserved dose least 1.5 x 107 TNC/kg . If unit contain red cell time cryopreservation , cryopreserved dose must least 2.0 x 107 TNC/kg . Each unit must least 4/6 HLAA B antigen , DRB1 allele match recipient . Each unit must least 3/6 HLAA , B DRB1 antigen match . Patient suitable relate donor AML , ALL , AUL , biphenotypic leukemia beyond CR2 AML evolve myelofibrosis Any acute leukemia : Morphologic relapse persistent disease BM Active extramedullary leukemia include active CNS leukemia Requiring great two cycle chemotherapy obtain present remission status Bone marrow aplasia ( define BM cellularity &lt; 5 % transplant workup ) MDS 10 % great bone marrow blast pretransplant workup Prior autologous allogeneic HSC transplant time Prior radiation therapy render patient ineligible TBI Any uncontrolled infection time study enrollment Seropositive NAT positive HIV HTLV1 Females pregnant breast feeding Patient unable give inform consent unable comply treatment protocol include appropriate supportive care , followup , research test</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cord Blood Stem Cell Transplantation</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>